Feasibility of Self-treatment of Painful Diabetic Neuropathy Using Electrical Vasomotor Nerve Stimulation

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Electrical stimulation with EVNS (Electrical Vasomotor Neuro Stimulation), a methodology used by a specific group of neurostimulators known under various names, has proven its benefit in Painful Diabetic Neuropathy (PDN). However, due to the impaired mobility from Diabetic Neuropathy, a part of subjects did not finish the 10 days treatment in the outpatient clinic. Another part of the target group decided not to participate at all for the same reason. The current study investigates the feasibility, safety and performance of a newly developed EVNS device, called Releaf™, optimised for HOME treatment,

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Painful Diabetic Neuropathy (DN4 positive) and insufficiently treated with any combination of 2 of the following drugs: Duloxetine (Cymbalta), venlafaxine (Efexor), ami- or nortriptyline, gabapentine, pregabaline (Lyrica) or the use of carbamazepine or capsaïcine (Qutenza).

• Both feet are present

• Able and willing to complete the treatments in 10 days in a row and completion of questionnaires.

• Being in a mental and physical state to perform home self-treatment with Releaf™ for 10 consecutive days, if necessary with adequate assistance of caregiver.

• Being in a mental and physical state to understand and complete the informed consent form as well as the research questionnaires.

Locations
Other Locations
Netherlands
Neurecon
RECRUITING
Vught
Contact Information
Primary
Hans Kerssemakers, MSc
hans.kerssemakers@neurecon.com
+3173-2340747
Time Frame
Start Date: 2024-07-22
Estimated Completion Date: 2024-12
Participants
Target number of participants: 40
Treatments
Experimental: EVNS treatment
EVNS, see intervention
Related Therapeutic Areas
Sponsors
Leads: Neurecon BV

This content was sourced from clinicaltrials.gov